Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors

Michael Martin, John F. Dipersio, Geoffrey L. Uy

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Imatinib has revolutionised the management of chronic phase chronic myelogenous leukemia (CML). Unfortunately it has had less of an impact on the management of the advanced phases of CML. These historically difficult-to-treat phases of disease remain largely resistant to therapy. Even when responses are obtained with the tyrosine kinase inhibitors, they are brief, particularly in blast phase (BP) disease. Allogeneic stem cell transplantation is the only curative option for these patients and should be considered early as an integral part of the treatment plan. But transplant outcomes are dependent on cytogenetic and gross disease burden at the time of transplant. This review will compare and contrast the various tyrosine kinase- and non-tyrosine kinase inhibitor-based treatments for accelerated and BP CML before allogeneic transplantation.

Original languageEnglish (US)
Pages (from-to)14-23
Number of pages10
JournalLeukemia and Lymphoma
Volume50
Issue number1
DOIs
StatePublished - Feb 6 2009

Fingerprint

Leukemia, Myeloid, Chronic Phase
Protein-Tyrosine Kinases
Blast Crisis
Transplants
Homologous Transplantation
Stem Cell Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Phosphotransferases
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. / Martin, Michael; Dipersio, John F.; Uy, Geoffrey L.

In: Leukemia and Lymphoma, Vol. 50, No. 1, 06.02.2009, p. 14-23.

Research output: Contribution to journalReview article

@article{a842f50c3ffa44339bbcbfa6a2899fc9,
title = "Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors",
abstract = "Imatinib has revolutionised the management of chronic phase chronic myelogenous leukemia (CML). Unfortunately it has had less of an impact on the management of the advanced phases of CML. These historically difficult-to-treat phases of disease remain largely resistant to therapy. Even when responses are obtained with the tyrosine kinase inhibitors, they are brief, particularly in blast phase (BP) disease. Allogeneic stem cell transplantation is the only curative option for these patients and should be considered early as an integral part of the treatment plan. But transplant outcomes are dependent on cytogenetic and gross disease burden at the time of transplant. This review will compare and contrast the various tyrosine kinase- and non-tyrosine kinase inhibitor-based treatments for accelerated and BP CML before allogeneic transplantation.",
author = "Michael Martin and Dipersio, {John F.} and Uy, {Geoffrey L.}",
year = "2009",
month = "2",
day = "6",
doi = "10.1080/10428190802517765",
language = "English (US)",
volume = "50",
pages = "14--23",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors

AU - Martin, Michael

AU - Dipersio, John F.

AU - Uy, Geoffrey L.

PY - 2009/2/6

Y1 - 2009/2/6

N2 - Imatinib has revolutionised the management of chronic phase chronic myelogenous leukemia (CML). Unfortunately it has had less of an impact on the management of the advanced phases of CML. These historically difficult-to-treat phases of disease remain largely resistant to therapy. Even when responses are obtained with the tyrosine kinase inhibitors, they are brief, particularly in blast phase (BP) disease. Allogeneic stem cell transplantation is the only curative option for these patients and should be considered early as an integral part of the treatment plan. But transplant outcomes are dependent on cytogenetic and gross disease burden at the time of transplant. This review will compare and contrast the various tyrosine kinase- and non-tyrosine kinase inhibitor-based treatments for accelerated and BP CML before allogeneic transplantation.

AB - Imatinib has revolutionised the management of chronic phase chronic myelogenous leukemia (CML). Unfortunately it has had less of an impact on the management of the advanced phases of CML. These historically difficult-to-treat phases of disease remain largely resistant to therapy. Even when responses are obtained with the tyrosine kinase inhibitors, they are brief, particularly in blast phase (BP) disease. Allogeneic stem cell transplantation is the only curative option for these patients and should be considered early as an integral part of the treatment plan. But transplant outcomes are dependent on cytogenetic and gross disease burden at the time of transplant. This review will compare and contrast the various tyrosine kinase- and non-tyrosine kinase inhibitor-based treatments for accelerated and BP CML before allogeneic transplantation.

UR - http://www.scopus.com/inward/record.url?scp=59249090119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59249090119&partnerID=8YFLogxK

U2 - 10.1080/10428190802517765

DO - 10.1080/10428190802517765

M3 - Review article

VL - 50

SP - 14

EP - 23

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -